Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

CVS, Walmart reach $147.5 million opioid settlement with West Virginia

Published 09/20/2022, 03:31 PM
Updated 09/20/2022, 05:21 PM
© Reuters. FILE PHOTO: People walk by a CVS pharmacy store in Manhattan, New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly

By Dietrich Knauth

(Reuters) -CVS Health Corp and Walmart (NYSE:WMT) Inc have agreed to pay $147.5 million to settle West Virginia's claims over their alleged roles in the state's opioid crisis, state attorney general Patrick Morrisey said Tuesday.

CVS agreed to pay $82.5 million and Walmart agreed to pay approximately $65 million, according to the state.

West Virginia had been prepared to proceed to trial on Sept. 26 against the two companies, as well as Walgreens Boots Alliance (NASDAQ:WBA).

The state had accused the pharmacy chains of fueling the deadly opioid epidemic through their allegedly lax oversight of prescription pills sold in the state.

Walgreens has not settled, and a trial has been rescheduled for June 2023.

"We believe that we have a very strong case against Walgreens," Morrisey said at a news conference. "We're going to pursue that quite vigorously."

Kroger (NYSE:KR) Co. will also be a defendant in the rescheduled June 2023 trial.

West Virginia has been particularly hard hit by the epidemic, with a per capita opioid mortality rate over three times the national average in 2020, according to data from the National Center for Health Statistics.

CVS said that it will continue to defend itself in other opioid lawsuits, but believed that "putting these claims behind us" was the right decision in the West Virginia case.

"Our position remains that opioid prescriptions are written by doctors, not pharmacists, and that opioid medications are made and marketed by manufacturers, not pharmacies," CVS spokesman Michael DeAngelis said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Walmart and Walgreens did not immediately respond to a request for comment.

More than 3,300 lawsuits have been filed against drugmakers, distributors and pharmacies over the crisis.

The litigation has increasingly targeted pharmacy chains in recent months, after drug makers and distributors reached major nationwide settlements, including a $26 billion deal with the three leading drug distributors and Johnson & Johnson (NYSE:JNJ), addressing their liabilities.

Walgreens has resisted settlements in other opioid cases brought by state and local governments this year. It was the last defendant to settle a lawsuit over Florida's opioid claims, and it was the sole defendant to go to trial over San Francisco's opioid claims.

Walgreens was found liable for fueling opioid addiction in San Francisco, and the amount it must pay will be determined in a future trial.

Walgreens, CVS and Walmart were found liable for contributing to the opioid crisis in two Ohio counties, and were ordered to pay $650 million in that case.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.